2017 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated with Belatacept.
Emory Transplant Center, Atlanta, GA
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to allograft loss. A recently…2017 American Transplant Congress
Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?
Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI…2017 American Transplant Congress
Clinic-Based Medication Education Pilot Program.
1Henry Ford Hospital, Detroit, MI; 2University of Kentucky, Lexington, KY
Purpose: Adherence to medications is crucial for transplant patients as missing medications can result in increased risk of rejection and graft loss. Augmented education may…2017 American Transplant Congress
Type of Surgical Procedures and Clinical Significance of Calcineurin Inhibitor Temporary Discontinuation Regarding LT Recipients Undergoing Major Elective Surgery.
Surgery, Samsung Medical Center, Seoul, Republic of Korea
Background As patients increasingly have undergone live transplantation (LT) and improved expected survival rate, there is a growing population of LT recipient undergoing elective surgery…2017 American Transplant Congress
Molecular Profiles of Renal Allograft Biopsies at 12 Months Post Renal Transplant in Patients Exposed to Low Dose CNI and Everolimus vs. Patients Exposed to Full Dose CNI and MMF.
CNIs serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize that lower…2017 American Transplant Congress
Impact of mTOR-Inhibition on Tolerance-Induction Following Heart Transplantation.
Clinic for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany
Introduction: The mammalian target of rapamycin (mTOR) is a central regulator of the immune system and therefore one target of immunosuppressive drug therapy. Tolerance-inducing properties…2017 American Transplant Congress
Utility of Weighted Composite Endpoints in Kidney Transplantation.
Cleveland Clinic, Cleveland, OH
IntroductionAdvances in therapeutic development and innovation are stifled in transplantation based on difficulties demonstrating efficacy of novel interventions using standard endpoints. Current RCTs are constrained…2017 American Transplant Congress
Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.
BACKGROUNDPretransplant desensitization with rituximab has contributed to drastic improvements in ABO-incompatible renal transplantation (ABO-I). However, ABO-I outcomes are still worse than those of ABO-identical or…2017 American Transplant Congress
Risk Factors for Polyomavirus Infection After Renal Transplantation: Introduction of the Protective Effect of Peritoneal Dialysis.
Medicine, Western University, London Health Sciences Centre, London, ON, Canada
Objective: To determine the roles of pre and post-transplant variables on the risk of BK virus infection after renal transplantation.Method: This study is a single-…2017 American Transplant Congress
The Adoption of Generic Immunosuppressant Medications Among Kidney and Liver Transplant Recipients Using the Colorado All Payer Claims Database.
Background: Substitution of generic for brand-name immunosuppressants has increased in solid organ transplantation following the expiration of brand patents. Our aim was to describe the…
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 138
- Next Page »